Related Experiment Video
Updated: May 24, 2025

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Innovative Algorithm for Incidence of Leukemia and Lymphoma in the U.S. Military Health Care System
Scott W Penney1,2, Nora L Watson3, Daniel I Brooks3
1Department of Pediatrics, Pediatric Hematology/Oncology Service, Brooke Army Medical Center, San Antonio, TX 78234, USA.
Introduction:
There is limited research on cancer incidence in pediatric and adolescent/young adult patients using health care claims data and no standard algorithm for such a query. This study aimed to establish an algorithm to estimate incidence rates for multiple cancer types from 2013 to 2017 within the Military Health System and compare them to rates reported from the National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) program.
Methods:
The Military Health System Data Repository was queried by International Classification of Diseases 9 and 10 codes using look-back-periods to identify incident cases of leukemia and lymphoma diagnoses. Age-specific incidence rates within the Military Health System were compared to SEER incidence rates using standardized incidence ratios (SIRs).
Results:
Military Health System incidences derived from our algorithm were similar to SEER incidences for all evaluated cancers in primary analyses. For pediatric dependents: Acute lymphoblastic leukemia (ALL) SIR 1.01 (95% CI, 0.91-1.12), acute myeloid leukemia (AML) 1.10 (95% CI, 0.86-1.36), Hodgkin's lymphoma 0.93 (95% CI, 0.73-1.16), and non-Hodgkin's lymphoma (NHL) 1.07 (95% CI, 0.88-1.28). For adult dependents: ALL SIR 1.09 (95% CI, 0.79-1.43), AML 1.19 (95% CI, 0.86-1.59), Hodgkin's lymphoma 1.19 (95% CI, 1.00-1.40), and NHL 0.85 (95% CI, 0.66-1.06). For active duty patients: ALL SIR 1.38 (95% CI, 0.96-1.87), AML 1.35 (95% CI, 0.94-1.84), Hodgkin's lymphoma 1.23 (95% CI, 1.01-1.48), and NHL 0.88 (95% CI, 0.67-1.12).
Discussion:
Pediatric incidence rates were similar when compared to SEER rates for leukemia and lymphoma type, suggesting that this algorithm may be used to capture the burden in the military pediatric population and serve as a research tool to evaluate cancer epidemiology and patient outcomes.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018